Hematopoietic SCT in Iranian children 1991–2012
This study presents the pediatric hematopoietic SCT (HSCT) activity in Iran between 1991 and 2012. Overall, 1105 fifteen-year-old or younger patients have undergone HSCT (975 allogeneic and 130 autologous). Annual HSCTs have been increasing steadily since 2007. HLA-matched siblings and other related...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2015-04, Vol.50 (4), p.517-522 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 522 |
|---|---|
| container_issue | 4 |
| container_start_page | 517 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 50 |
| creator | Hamidieh, A A Behfar, M Babaki, A E S Jalali, A Hosseini, A-S Jahani, M Alimoghaddam, K Ghavamzadeh, A |
| description | This study presents the pediatric hematopoietic SCT (HSCT) activity in Iran between 1991 and 2012. Overall, 1105 fifteen-year-old or younger patients have undergone HSCT (975 allogeneic and 130 autologous). Annual HSCTs have been increasing steadily since 2007. HLA-matched siblings and other related donors were the main source of HSCs, although since 2008 a national HLA registry has been established to fill the gap for patients lacking a related donor. Inherited abnormalities of RBCs (45.88%), leukemias (27.6%) and BM failure syndromes (11.94%) constituted the majority of HSCTs during this period. Two-year overall survival and disease-free survival rates for all patients were 74.2% (95% confidence interval (CI): 71.6–77) and 66.3% (95% CI: 63.5–69.3), respectively. Leading cause of death in allogeneic group was TRM (165 deaths) and relapse caused the majority of deaths in the autologous group (39 deaths). All HSCTs from the beginning have been performed exclusively with TBI-free-conditioning regimens, which provides unique data for comparison with activities of other centers. Encouraging survival rates provide a basis for future studies on the extensive applicability of TBI-free-conditioning regimens in pediatric HSCT. |
| doi_str_mv | 10.1038/bmt.2014.299 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1683354140</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A409833508</galeid><sourcerecordid>A409833508</sourcerecordid><originalsourceid>FETCH-LOGICAL-c516t-108f72fa634b23ea72061830f3ba19380fca9b15fd3930a34e5deea6611958b93</originalsourceid><addsrcrecordid>eNqN0s1qFTEUB_AgFnut7lzLgCAunGu-J1mWi9pCoQvrOmRmTnpTZpJrMrNw5zv4hn2SZrjVflBEsggkv5yTA3-E3hC8JpipT-04rSkmfE21foZWhDeyFkyK52iFqVQ1Y1Ifopc5X-GiOBYv0CEVQmsi1QqRExjtFHfRw-S76tvmovKhOk02eBuqbuuHPkGoSOHXv36XPvQVOnB2yPD6dj9C3798vtic1GfnX083x2d1J4icaoKVa6izkvGWMrANxZIohh1rLdFMYddZ3RLheqYZtoyD6AGslIRooVrNjtCHfd1dij9myJMZfe5gGGyAOGdTvs-Y4ITj_6BSc4GxloW-e0Sv4pxCGcRQySnljWLiX6rUarRgjKo7dWkHMD64OCXbLa3NMcd6-R5e1PoJVVYPo-9iAOfL-YMH7-892IIdpm2Owzz5GPJD-HEPuxRzTuDMLvnRpp-GYLNkw5RsmCUbpmSj8Le3Q83tCP1f_CcMBdR7kMtVuIR0b-qnCt4AajG74A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1667953328</pqid></control><display><type>article</type><title>Hematopoietic SCT in Iranian children 1991–2012</title><source>MEDLINE</source><source>Nature</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Hamidieh, A A ; Behfar, M ; Babaki, A E S ; Jalali, A ; Hosseini, A-S ; Jahani, M ; Alimoghaddam, K ; Ghavamzadeh, A</creator><creatorcontrib>Hamidieh, A A ; Behfar, M ; Babaki, A E S ; Jalali, A ; Hosseini, A-S ; Jahani, M ; Alimoghaddam, K ; Ghavamzadeh, A</creatorcontrib><description>This study presents the pediatric hematopoietic SCT (HSCT) activity in Iran between 1991 and 2012. Overall, 1105 fifteen-year-old or younger patients have undergone HSCT (975 allogeneic and 130 autologous). Annual HSCTs have been increasing steadily since 2007. HLA-matched siblings and other related donors were the main source of HSCs, although since 2008 a national HLA registry has been established to fill the gap for patients lacking a related donor. Inherited abnormalities of RBCs (45.88%), leukemias (27.6%) and BM failure syndromes (11.94%) constituted the majority of HSCTs during this period. Two-year overall survival and disease-free survival rates for all patients were 74.2% (95% confidence interval (CI): 71.6–77) and 66.3% (95% CI: 63.5–69.3), respectively. Leading cause of death in allogeneic group was TRM (165 deaths) and relapse caused the majority of deaths in the autologous group (39 deaths). All HSCTs from the beginning have been performed exclusively with TBI-free-conditioning regimens, which provides unique data for comparison with activities of other centers. Encouraging survival rates provide a basis for future studies on the extensive applicability of TBI-free-conditioning regimens in pediatric HSCT.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/bmt.2014.299</identifier><identifier>PMID: 25599168</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/532/1542 ; 692/308/2171 ; Abnormalities ; Adolescent ; Allografts ; Autografts ; Bone marrow ; Care and treatment ; Cell Biology ; Child ; Child, Preschool ; Childhood leukemia ; Conditioning ; Confidence intervals ; Disease-Free Survival ; Fatalities ; Female ; Forecasts and trends ; Hematologic Diseases - mortality ; Hematologic Diseases - therapy ; Hematology ; Hematopoietic Stem Cell Transplantation ; Histocompatibility antigen HLA ; Humans ; Infant ; Internal Medicine ; Iran ; Leukemia ; Male ; Medicine ; Medicine & Public Health ; Neoplasms - mortality ; Neoplasms - therapy ; original-article ; Patients ; Pediatrics ; Public Health ; Retrospective Studies ; Stem cell transplantation ; Stem Cells ; Survival ; Survival Rate ; Unrelated Donors</subject><ispartof>Bone marrow transplantation (Basingstoke), 2015-04, Vol.50 (4), p.517-522</ispartof><rights>Macmillan Publishers Limited 2015</rights><rights>COPYRIGHT 2015 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Apr 2015</rights><rights>Macmillan Publishers Limited 2015.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c516t-108f72fa634b23ea72061830f3ba19380fca9b15fd3930a34e5deea6611958b93</citedby><cites>FETCH-LOGICAL-c516t-108f72fa634b23ea72061830f3ba19380fca9b15fd3930a34e5deea6611958b93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25599168$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hamidieh, A A</creatorcontrib><creatorcontrib>Behfar, M</creatorcontrib><creatorcontrib>Babaki, A E S</creatorcontrib><creatorcontrib>Jalali, A</creatorcontrib><creatorcontrib>Hosseini, A-S</creatorcontrib><creatorcontrib>Jahani, M</creatorcontrib><creatorcontrib>Alimoghaddam, K</creatorcontrib><creatorcontrib>Ghavamzadeh, A</creatorcontrib><title>Hematopoietic SCT in Iranian children 1991–2012</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>This study presents the pediatric hematopoietic SCT (HSCT) activity in Iran between 1991 and 2012. Overall, 1105 fifteen-year-old or younger patients have undergone HSCT (975 allogeneic and 130 autologous). Annual HSCTs have been increasing steadily since 2007. HLA-matched siblings and other related donors were the main source of HSCs, although since 2008 a national HLA registry has been established to fill the gap for patients lacking a related donor. Inherited abnormalities of RBCs (45.88%), leukemias (27.6%) and BM failure syndromes (11.94%) constituted the majority of HSCTs during this period. Two-year overall survival and disease-free survival rates for all patients were 74.2% (95% confidence interval (CI): 71.6–77) and 66.3% (95% CI: 63.5–69.3), respectively. Leading cause of death in allogeneic group was TRM (165 deaths) and relapse caused the majority of deaths in the autologous group (39 deaths). All HSCTs from the beginning have been performed exclusively with TBI-free-conditioning regimens, which provides unique data for comparison with activities of other centers. Encouraging survival rates provide a basis for future studies on the extensive applicability of TBI-free-conditioning regimens in pediatric HSCT.</description><subject>631/532/1542</subject><subject>692/308/2171</subject><subject>Abnormalities</subject><subject>Adolescent</subject><subject>Allografts</subject><subject>Autografts</subject><subject>Bone marrow</subject><subject>Care and treatment</subject><subject>Cell Biology</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Childhood leukemia</subject><subject>Conditioning</subject><subject>Confidence intervals</subject><subject>Disease-Free Survival</subject><subject>Fatalities</subject><subject>Female</subject><subject>Forecasts and trends</subject><subject>Hematologic Diseases - mortality</subject><subject>Hematologic Diseases - therapy</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Histocompatibility antigen HLA</subject><subject>Humans</subject><subject>Infant</subject><subject>Internal Medicine</subject><subject>Iran</subject><subject>Leukemia</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoplasms - mortality</subject><subject>Neoplasms - therapy</subject><subject>original-article</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Public Health</subject><subject>Retrospective Studies</subject><subject>Stem cell transplantation</subject><subject>Stem Cells</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>Unrelated Donors</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqN0s1qFTEUB_AgFnut7lzLgCAunGu-J1mWi9pCoQvrOmRmTnpTZpJrMrNw5zv4hn2SZrjVflBEsggkv5yTA3-E3hC8JpipT-04rSkmfE21foZWhDeyFkyK52iFqVQ1Y1Ifopc5X-GiOBYv0CEVQmsi1QqRExjtFHfRw-S76tvmovKhOk02eBuqbuuHPkGoSOHXv36XPvQVOnB2yPD6dj9C3798vtic1GfnX083x2d1J4icaoKVa6izkvGWMrANxZIohh1rLdFMYddZ3RLheqYZtoyD6AGslIRooVrNjtCHfd1dij9myJMZfe5gGGyAOGdTvs-Y4ITj_6BSc4GxloW-e0Sv4pxCGcRQySnljWLiX6rUarRgjKo7dWkHMD64OCXbLa3NMcd6-R5e1PoJVVYPo-9iAOfL-YMH7-892IIdpm2Owzz5GPJD-HEPuxRzTuDMLvnRpp-GYLNkw5RsmCUbpmSj8Le3Q83tCP1f_CcMBdR7kMtVuIR0b-qnCt4AajG74A</recordid><startdate>20150401</startdate><enddate>20150401</enddate><creator>Hamidieh, A A</creator><creator>Behfar, M</creator><creator>Babaki, A E S</creator><creator>Jalali, A</creator><creator>Hosseini, A-S</creator><creator>Jahani, M</creator><creator>Alimoghaddam, K</creator><creator>Ghavamzadeh, A</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20150401</creationdate><title>Hematopoietic SCT in Iranian children 1991–2012</title><author>Hamidieh, A A ; Behfar, M ; Babaki, A E S ; Jalali, A ; Hosseini, A-S ; Jahani, M ; Alimoghaddam, K ; Ghavamzadeh, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c516t-108f72fa634b23ea72061830f3ba19380fca9b15fd3930a34e5deea6611958b93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>631/532/1542</topic><topic>692/308/2171</topic><topic>Abnormalities</topic><topic>Adolescent</topic><topic>Allografts</topic><topic>Autografts</topic><topic>Bone marrow</topic><topic>Care and treatment</topic><topic>Cell Biology</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Childhood leukemia</topic><topic>Conditioning</topic><topic>Confidence intervals</topic><topic>Disease-Free Survival</topic><topic>Fatalities</topic><topic>Female</topic><topic>Forecasts and trends</topic><topic>Hematologic Diseases - mortality</topic><topic>Hematologic Diseases - therapy</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Histocompatibility antigen HLA</topic><topic>Humans</topic><topic>Infant</topic><topic>Internal Medicine</topic><topic>Iran</topic><topic>Leukemia</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoplasms - mortality</topic><topic>Neoplasms - therapy</topic><topic>original-article</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Public Health</topic><topic>Retrospective Studies</topic><topic>Stem cell transplantation</topic><topic>Stem Cells</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>Unrelated Donors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hamidieh, A A</creatorcontrib><creatorcontrib>Behfar, M</creatorcontrib><creatorcontrib>Babaki, A E S</creatorcontrib><creatorcontrib>Jalali, A</creatorcontrib><creatorcontrib>Hosseini, A-S</creatorcontrib><creatorcontrib>Jahani, M</creatorcontrib><creatorcontrib>Alimoghaddam, K</creatorcontrib><creatorcontrib>Ghavamzadeh, A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hamidieh, A A</au><au>Behfar, M</au><au>Babaki, A E S</au><au>Jalali, A</au><au>Hosseini, A-S</au><au>Jahani, M</au><au>Alimoghaddam, K</au><au>Ghavamzadeh, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hematopoietic SCT in Iranian children 1991–2012</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2015-04-01</date><risdate>2015</risdate><volume>50</volume><issue>4</issue><spage>517</spage><epage>522</epage><pages>517-522</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><abstract>This study presents the pediatric hematopoietic SCT (HSCT) activity in Iran between 1991 and 2012. Overall, 1105 fifteen-year-old or younger patients have undergone HSCT (975 allogeneic and 130 autologous). Annual HSCTs have been increasing steadily since 2007. HLA-matched siblings and other related donors were the main source of HSCs, although since 2008 a national HLA registry has been established to fill the gap for patients lacking a related donor. Inherited abnormalities of RBCs (45.88%), leukemias (27.6%) and BM failure syndromes (11.94%) constituted the majority of HSCTs during this period. Two-year overall survival and disease-free survival rates for all patients were 74.2% (95% confidence interval (CI): 71.6–77) and 66.3% (95% CI: 63.5–69.3), respectively. Leading cause of death in allogeneic group was TRM (165 deaths) and relapse caused the majority of deaths in the autologous group (39 deaths). All HSCTs from the beginning have been performed exclusively with TBI-free-conditioning regimens, which provides unique data for comparison with activities of other centers. Encouraging survival rates provide a basis for future studies on the extensive applicability of TBI-free-conditioning regimens in pediatric HSCT.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>25599168</pmid><doi>10.1038/bmt.2014.299</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2015-04, Vol.50 (4), p.517-522 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1683354140 |
| source | MEDLINE; Nature; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | 631/532/1542 692/308/2171 Abnormalities Adolescent Allografts Autografts Bone marrow Care and treatment Cell Biology Child Child, Preschool Childhood leukemia Conditioning Confidence intervals Disease-Free Survival Fatalities Female Forecasts and trends Hematologic Diseases - mortality Hematologic Diseases - therapy Hematology Hematopoietic Stem Cell Transplantation Histocompatibility antigen HLA Humans Infant Internal Medicine Iran Leukemia Male Medicine Medicine & Public Health Neoplasms - mortality Neoplasms - therapy original-article Patients Pediatrics Public Health Retrospective Studies Stem cell transplantation Stem Cells Survival Survival Rate Unrelated Donors |
| title | Hematopoietic SCT in Iranian children 1991–2012 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T20%3A10%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hematopoietic%20SCT%20in%20Iranian%20children%201991%E2%80%932012&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Hamidieh,%20A%20A&rft.date=2015-04-01&rft.volume=50&rft.issue=4&rft.spage=517&rft.epage=522&rft.pages=517-522&rft.issn=0268-3369&rft.eissn=1476-5365&rft_id=info:doi/10.1038/bmt.2014.299&rft_dat=%3Cgale_proqu%3EA409833508%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1667953328&rft_id=info:pmid/25599168&rft_galeid=A409833508&rfr_iscdi=true |